First Time Loading...

Kymera Therapeutics Inc
NASDAQ:KYMR

Watchlist Manager
Kymera Therapeutics Inc Logo
Kymera Therapeutics Inc
NASDAQ:KYMR
Watchlist
Price: 36.24 USD 7.79% Market Closed
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

KYMR Price Targets Summary
Kymera Therapeutics Inc

Wall Street analysts forecast KYMR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KYMR is 52.26 USD with a low forecast of 30.3 USD and a high forecast of 117.6 USD.

KYMR Lowest Forecast
Wall Street Target
30.3 USD
16% Downside
KYMR Average Forecast
Wall Street Target
52.26 USD
44% Upside
KYMR Highest Forecast
Wall Street Target
117.6 USD
225% Upside
Lowest
Price Target
30.3 USD
16% Downside
Average
Price Target
52.26 USD
44% Upside
Highest
Price Target
117.6 USD
225% Upside
Kymera Therapeutics Inc Competitors:
Price Targets
MYGN
Myriad Genetics Inc
28% Upside
PBYI
Puma Biotechnology Inc
11% Downside
FHTX
Foghorn Therapeutics Inc.
136% Upside
IMMU
Mendus AB (publ)
309% Upside
MYGN
Myriad Genetics Inc
28% Upside
PBYI
Puma Biotechnology Inc
11% Downside
FHTX
Foghorn Therapeutics Inc.
136% Upside
IMMU
Mendus AB (publ)
309% Upside
T
1875
TOT BIOPHARM International Co Ltd
123% Upside
ALKS
Alkermes Plc
55% Upside
CDTX
Cidara Therapeutics Inc
412% Upside
B
600161
Beijing Tiantan Biological Products Corp Ltd
16% Upside

Revenue
Forecast

Revenue Estimate
Kymera Therapeutics Inc

For the last 4 years the compound annual growth rate for Kymera Therapeutics Inc's revenue is 128%. The projected CAGR for the next 3 years is -3%.

128%
Past Growth
-3%
Estimated Growth
Estimates Accuracy
-10%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Kymera Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
6%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Kymera Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
What are analyst estimates?

See Also

Summary
KYMR intrinsic value, competitors valuation, and company profile.
DCF Valuation
KYMR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KYMR stock valuation using valuation multiples.
Wall Street Estimates
KYMR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KYMR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KYMR's stock price target?
Price Target
52.26 USD

According to Wall Street analysts, the average 1-year price target for KYMR is 52.26 USD with a low forecast of 30.3 USD and a high forecast of 117.6 USD.

What is Kymera Therapeutics Inc's Revenue forecast?
Projected CAGR
-3%

For the last 4 years the compound annual growth rate for Kymera Therapeutics Inc's revenue is 128%. The projected CAGR for the next 3 years is -3%.

ALPHA SPREAD
Join more than 133,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.